A phase II study of 5-fluorouracil, leucovorin and interferon-α in advanced pancreatic cancer

M. J. Moore, C. Erlichman, L. Kaizer, S. Fine

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Increased activity against colorectal cancer by 5-fluorouracil (5-Fu) modulation with leucovorin (LV) and/or interferon (IFN) has been reported. In this study 22 patients with measurable advanced pancreatic cancer received 5-Fu 375 mg/m2 and LV 20 mg/m2 by i.v. bolus daily x5 every 28 days plus IFN-α 3 million units/m2 s.c. There were three out of 21 (14%) responses lasting from 4 to 8 months. Sixteen patients (73%) had one or more episodes of grade 3 or greater toxicity (stomatitis, diarrhea or fatigue). While this combination has some activity against pancreatic cancer, its toxicity limits its potential as a palliative treatment.

Original languageEnglish (US)
Pages (from-to)555-557
Number of pages3
JournalAnti-Cancer Drugs
Volume4
Issue number5
StatePublished - 1993
Externally publishedYes

Fingerprint

Leucovorin
Pancreatic Neoplasms
Fluorouracil
Interferons
Stomatitis
Palliative Care
Fatigue
Colorectal Neoplasms
Diarrhea

Keywords

  • 5-Fluorouracil
  • Interferon
  • Leucovorin
  • Pancreatic cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Moore, M. J., Erlichman, C., Kaizer, L., & Fine, S. (1993). A phase II study of 5-fluorouracil, leucovorin and interferon-α in advanced pancreatic cancer. Anti-Cancer Drugs, 4(5), 555-557.

A phase II study of 5-fluorouracil, leucovorin and interferon-α in advanced pancreatic cancer. / Moore, M. J.; Erlichman, C.; Kaizer, L.; Fine, S.

In: Anti-Cancer Drugs, Vol. 4, No. 5, 1993, p. 555-557.

Research output: Contribution to journalArticle

Moore, MJ, Erlichman, C, Kaizer, L & Fine, S 1993, 'A phase II study of 5-fluorouracil, leucovorin and interferon-α in advanced pancreatic cancer', Anti-Cancer Drugs, vol. 4, no. 5, pp. 555-557.
Moore, M. J. ; Erlichman, C. ; Kaizer, L. ; Fine, S. / A phase II study of 5-fluorouracil, leucovorin and interferon-α in advanced pancreatic cancer. In: Anti-Cancer Drugs. 1993 ; Vol. 4, No. 5. pp. 555-557.
@article{6e15b3aee59f49f9b7f9de0611e73207,
title = "A phase II study of 5-fluorouracil, leucovorin and interferon-α in advanced pancreatic cancer",
abstract = "Increased activity against colorectal cancer by 5-fluorouracil (5-Fu) modulation with leucovorin (LV) and/or interferon (IFN) has been reported. In this study 22 patients with measurable advanced pancreatic cancer received 5-Fu 375 mg/m2 and LV 20 mg/m2 by i.v. bolus daily x5 every 28 days plus IFN-α 3 million units/m2 s.c. There were three out of 21 (14{\%}) responses lasting from 4 to 8 months. Sixteen patients (73{\%}) had one or more episodes of grade 3 or greater toxicity (stomatitis, diarrhea or fatigue). While this combination has some activity against pancreatic cancer, its toxicity limits its potential as a palliative treatment.",
keywords = "5-Fluorouracil, Interferon, Leucovorin, Pancreatic cancer",
author = "Moore, {M. J.} and C. Erlichman and L. Kaizer and S. Fine",
year = "1993",
language = "English (US)",
volume = "4",
pages = "555--557",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A phase II study of 5-fluorouracil, leucovorin and interferon-α in advanced pancreatic cancer

AU - Moore, M. J.

AU - Erlichman, C.

AU - Kaizer, L.

AU - Fine, S.

PY - 1993

Y1 - 1993

N2 - Increased activity against colorectal cancer by 5-fluorouracil (5-Fu) modulation with leucovorin (LV) and/or interferon (IFN) has been reported. In this study 22 patients with measurable advanced pancreatic cancer received 5-Fu 375 mg/m2 and LV 20 mg/m2 by i.v. bolus daily x5 every 28 days plus IFN-α 3 million units/m2 s.c. There were three out of 21 (14%) responses lasting from 4 to 8 months. Sixteen patients (73%) had one or more episodes of grade 3 or greater toxicity (stomatitis, diarrhea or fatigue). While this combination has some activity against pancreatic cancer, its toxicity limits its potential as a palliative treatment.

AB - Increased activity against colorectal cancer by 5-fluorouracil (5-Fu) modulation with leucovorin (LV) and/or interferon (IFN) has been reported. In this study 22 patients with measurable advanced pancreatic cancer received 5-Fu 375 mg/m2 and LV 20 mg/m2 by i.v. bolus daily x5 every 28 days plus IFN-α 3 million units/m2 s.c. There were three out of 21 (14%) responses lasting from 4 to 8 months. Sixteen patients (73%) had one or more episodes of grade 3 or greater toxicity (stomatitis, diarrhea or fatigue). While this combination has some activity against pancreatic cancer, its toxicity limits its potential as a palliative treatment.

KW - 5-Fluorouracil

KW - Interferon

KW - Leucovorin

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=0027432954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027432954&partnerID=8YFLogxK

M3 - Article

C2 - 8292812

AN - SCOPUS:0027432954

VL - 4

SP - 555

EP - 557

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 5

ER -